245 related articles for article (PubMed ID: 36707462)
1. Polymorphic Alpha-Synuclein Oligomers: Characterization and Differential Detection with Novel Corresponding Antibodies.
Moore K; Sengupta U; Puangmalai N; Bhatt N; Kayed R
Mol Neurobiol; 2023 May; 60(5):2691-2705. PubMed ID: 36707462
[TBL] [Abstract][Full Text] [Related]
2. Polymorphic α-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein.
Sengupta U; Puangmalai N; Bhatt N; Garcia S; Zhao Y; Kayed R
Mol Neurobiol; 2020 Jun; 57(6):2741-2765. PubMed ID: 32350746
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
[TBL] [Abstract][Full Text] [Related]
4. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.
Tsika E; Moysidou M; Guo J; Cushman M; Gannon P; Sandaltzopoulos R; Giasson BI; Krainc D; Ischiropoulos H; Mazzulli JR
J Neurosci; 2010 Mar; 30(9):3409-18. PubMed ID: 20203200
[TBL] [Abstract][Full Text] [Related]
5. Selectivity of Lewy body protein interactions along the aggregation pathway of α-synuclein.
Leitão ADG; Rudolffi-Soto P; Chappard A; Bhumkar A; Lau D; Hunter DJB; Gambin Y; Sierecki E
Commun Biol; 2021 Sep; 4(1):1124. PubMed ID: 34556785
[TBL] [Abstract][Full Text] [Related]
6. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
[TBL] [Abstract][Full Text] [Related]
7. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
[TBL] [Abstract][Full Text] [Related]
8. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
[TBL] [Abstract][Full Text] [Related]
9. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.
Doucet M; El-Turabi A; Zabel F; Hunn BHM; Bengoa-Vergniory N; Cioroch M; Ramm M; Smith AM; Gomes AC; Cabral de Miranda G; Wade-Martins R; Bachmann MF
PLoS One; 2017; 12(8):e0181844. PubMed ID: 28797124
[TBL] [Abstract][Full Text] [Related]
10. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
11. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies.
Paleologou KE; Kragh CL; Mann DM; Salem SA; Al-Shami R; Allsop D; Hassan AH; Jensen PH; El-Agnaf OM
Brain; 2009 Apr; 132(Pt 4):1093-101. PubMed ID: 19155272
[TBL] [Abstract][Full Text] [Related]
12. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.
Nimmo JT; Verma A; Dodart JC; Wang CY; Savistchenko J; Melki R; Carare RO; Nicoll JAR
Alzheimers Res Ther; 2020 Nov; 12(1):159. PubMed ID: 33256825
[TBL] [Abstract][Full Text] [Related]
13. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
[TBL] [Abstract][Full Text] [Related]
14. Stabilization of α-synuclein oligomers using formaldehyde.
Ruesink H; Reimer L; Gregersen E; Moeller A; Betzer C; Jensen PH
PLoS One; 2019; 14(10):e0216764. PubMed ID: 31603909
[TBL] [Abstract][Full Text] [Related]
15. The small aromatic compound SynuClean-D inhibits the aggregation and seeded polymerization of multiple α-synuclein strains.
Peña-Díaz S; Pujols J; Vasili E; Pinheiro F; Santos J; Manglano-Artuñedo Z; Outeiro TF; Ventura S
J Biol Chem; 2022 May; 298(5):101902. PubMed ID: 35390347
[TBL] [Abstract][Full Text] [Related]
16. Liquid-liquid Phase Separation of α-Synuclein: A New Mechanistic Insight for α-Synuclein Aggregation Associated with Parkinson's Disease Pathogenesis.
Mukherjee S; Sakunthala A; Gadhe L; Poudyal M; Sawner AS; Kadu P; Maji SK
J Mol Biol; 2023 Jan; 435(1):167713. PubMed ID: 35787838
[TBL] [Abstract][Full Text] [Related]
17. α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies.
Prots I; Grosch J; Brazdis RM; Simmnacher K; Veber V; Havlicek S; Hannappel C; Krach F; Krumbiegel M; Schütz O; Reis A; Wrasidlo W; Galasko DR; Groemer TW; Masliah E; Schlötzer-Schrehardt U; Xiang W; Winkler J; Winner B
Proc Natl Acad Sci U S A; 2018 Jul; 115(30):7813-7818. PubMed ID: 29991596
[TBL] [Abstract][Full Text] [Related]
18. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.
Peng C; Gathagan RJ; Lee VM
Neurobiol Dis; 2018 Jan; 109(Pt B):209-218. PubMed ID: 28751258
[TBL] [Abstract][Full Text] [Related]
19. Could α-synuclein amyloid-like aggregates trigger a prionic neuronal invasion?
Busquets MA; Espargaró A; Estelrich J; Sabate R
Biomed Res Int; 2015; 2015():172018. PubMed ID: 25866763
[TBL] [Abstract][Full Text] [Related]
20. The good and bad of therapeutic strategies that directly target α-synuclein.
Longhena F; Faustini G; Brembati V; Pizzi M; Bellucci A
IUBMB Life; 2020 Apr; 72(4):590-600. PubMed ID: 31693290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
